Article
Pharmacology & Pharmacy
Xiao Liu, Lili Zhang, Yueying Yang, Weiwei Yin, Yunhu Liu, Chunyi Luo, Ruizhe Zhang, Zhiguo Long, Yanyan Jiang, Bing Wang
Summary: Arsenic trioxide (ATO) has been clinically used as a reliable and effective frontline drug for the treatment of acute promyelocytic leukemia (APL). However, its administration regimen is limited due to fast clearance, short therapeutic window, and toxicity. This study developed transferrin-modified liposomes encapsulating AsIII to improve its therapeutic efficacy. The AsIII-loaded liposomes exhibited acid-sensitive release and specifically targeted APL cells, leading to apoptosis and cell differentiation. Combining transferrin-modified retinoic acid liposomes further enhanced the tumor inhibition effect. The results suggest that transferrin-modified AsIII liposomes could be a novel clinical strategy for APL treatment with reduced systemic toxicity and improved efficacy.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Article
Pediatrics
Jong Hyeon Lee, Jong Ho Lee, Jae Min Lee
Summary: While ATRA is effective in treating APL, it may lead to side effects such as hearing loss. This case demonstrates that reducing the dose of ATRA and administering dexamethasone can successfully reverse ATRA-associated hearing loss. Conducting a randomized clinical trial using dexamethasone in combination with ATRA is recommended to prevent hearing loss caused by ATRA.
Review
Chemistry, Medicinal
Antonia Goncalves, Fernando Rocha, Berta N. Estevinho
Summary: Acute promyelocytic leukemia (APL) is a type of leukemia characterized by genetic abnormalities and the accumulation of abnormal promyelocytes. All-trans retinoic acid (all-trans RA) has dramatically improved the treatment of APL by promoting the differentiation of leukemic cells. Encapsulation technology using microparticle formulations obtained by spray-drying is being explored as an innovative strategy to improve the oral administration of all-trans RA. The goal is to develop a controlled delivery system that can provide a slow release of the drug in the intestines.
Article
Oncology
Francesco Autore, Patrizia Chiusolo, Federica Sora, Sabrina Giammarco, Luca Laurenti, Idanna Innocenti, Elisabetta Metafuni, Nicola Piccirillo, Livio Pagano, Simona Sica
Summary: Acute promyelocytic leukemia is a variant of acute myeloid leukemia characterized by t(15;17) and PML/RAR alfa fusion gene. Treatment with a combination of all-trans retinoic acid and arsenic trioxide has shown high efficacy and tolerability, providing an alternative to chemotherapy for selected patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Kensuke Matsuda, Taisuke Jo, Kazuhiro Toyama, Kumi Nakazaki, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga, Mineo Kurokawa
Summary: The study aimed to identify factors associated with in-hospital death in APL patients with coagulopathy during induction therapy. Older age, delayed initiation of ATRA, and lack of conventional chemotherapy were significantly linked to higher in-hospital mortality. While 63% of patients received anticoagulant therapies, these were not associated with reduced mortality, highlighting the poor prognosis of untreated APL patients, especially the elderly. Immediate administration of ATRA may help lower in-hospital mortality.
ANNALS OF HEMATOLOGY
(2021)
Review
Chemistry, Medicinal
Chengyuan Liang, Guaiping Qiao, Yuzhi Liu, Lei Tian, Nan Hui, Juan Li, Yuling Ma, Han Li, Qianqian Zhao, Wenqiang Cao, Hong Liu, Xiaodong Ren
Summary: All-trans-retinoic acid (ATRA) is effective in preventing cancer and treating skin diseases and acute promyelocytic leukaemia (APL) by regulating differentiation-related gene transcription and autophagy through inhibiting mTOR. A total of 68 ATRA analogues show promising antitumour therapeutic potential for further development and research.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Medicinal
Laia Josa-Cullere, Katrina S. Madden, Thomas J. Cogswell, Thomas R. Jackson, Tom S. Carter, Douzi Zhang, Graham Trevitt, Stephen G. Davies, Paresh Vyas, Graham M. Wynne, Thomas A. Milne, Angela J. Russell
Summary: A novel compound, OXS007417, identified through a phenotypic high-throughput screen, shows promise in decreasing tumor volume in acute myeloid leukemia.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Pharmacology & Pharmacy
Gabriel Silva Marques Borges, Flavia Alves Lima, Guilherme Carneiro, Gisele Assis Castro Goulart, Lucas Antonio Miranda Ferreira
Summary: All-trans retinoic acid (ATRA) is effective in treating acute promyelocytic leukemia (APL) but less so in other types of cancer. Nanotechnology shows promise in enhancing ATRA's anticancer activities and overcoming its limitations, such as bioavailability and resistance issues.
EXPERT OPINION ON DRUG DELIVERY
(2021)
Article
Oncology
Li Chen, Hongming Zhu, Yongmei Zhu, Wen Jin, Fangyi Dong, Jianfeng Li, Jiong Hu, Qiusheng Chen, Kankan Wang, Junmin Li
Summary: This study reported a rare case of BCOR-RARA variant APL and suggested that allo-HSCT after ATRA combined with chemotherapy is the optimal choice for vAPL patients with a high risk of relapse.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Marcus J. Geer, Charles E. Foucar, Sumana Devata, Lydia Benitez, Anthony J. Perissinotti, Bernard L. Marini, Dale Bixby
Summary: Less than one-third of hospitals in the United States had ATRA in stock, and hospitals treating patients with APL were more likely to have ATRA available compared to referring centers. These findings suggest a need to ensure immediate availability of ATRA for patients suspected of having APL.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Review
Oncology
Andrei Colita, Alina Daniela Tanase, Ciprian Tomuleasa, Anca Colita
Summary: Acute promyelocytic leukemia (APL) patients who relapse, despite treatment with all-trans retinoic acid and arsenic trioxide, require a highly efficient consolidation treatment. Hematopoietic stem cell transplantation is recommended for these patients. However, there are still controversies regarding the role of transplantation in APL and further studies are needed.
Article
Medicine, General & Internal
Xiaowei Shi, Shuangyue Li, Shanhao Tang, Ying Lu
Summary: Acute promyelocytic leukemia is a special subtype of acute myeloid leukemia with a high incidence of early death and complications. A new treatment strategy using oral all-trans retinoic acid combined with the realgar-indigo naturalis formula has shown effectiveness in patients with this condition.
Article
Medicine, General & Internal
Kensuke Matsuda, Takashi Oyama, Hiroaki Maki, Kumi Nakazaki, Megumi Yasunaga, Akira Honda, Yosuke Masamoto, Mineo Kurokawa
Summary: This study evaluated the management strategy for preventing early death in untreated acute promyelocytic leukemia (APL) patients. The results showed that compared to the national survey, a higher proportion of patients at our institute received conventional chemotherapy in addition to all-trans retinoic acid (ATRA) and treatment was initiated more promptly, potentially preventing early death.
Article
Immunology
Dongbei Li, Haijun Li, Cheng Cheng, Gangping Li, Fangfang Yuan, Ruihua Mi, Xiaojiao Wang, Ding Li, Ruihua Fan, Xudong Wei
Summary: The combination therapy of all-trans retinoic acid (ATRA) and ABT-199 shows a synergistic antileukemic effect by inducing apoptosis and cell cycle arrest in acute myeloid leukemia (AML) cells. In vivo, this combination therapy prolongs the survival of AML xenograft mice. The study provides a potential treatment strategy and theoretical support for overcoming the clinical ABT-199 resistance problem in AML patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Yusra Hashmi, Shehzeen F. Memon, Yasir A. Khan, Naeem Jabbar, Neelum Mansoor
Summary: ATRA therapy for acute promyelocytic leukemia can lead to hypercalcemia, especially when used concomitantly with antifungal drugs like voriconazole. Close monitoring and prompt discontinuation of medications may be necessary to manage hypercalcemia in such cases.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)